Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center-Reference-Cited by-同舟云学术

Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center

Published:2020-06 Issue:6 Volume:203 Page:1117-1121
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Carlsson Sigrid¹²³,Benfante Nicole¹,Alvim Ricardo¹,Sjoberg Daniel D.²,Vickers Andrew²,Reuter Victor E.⁴,Fine Samson W.⁴,Vargas Hebert Alberto⁵,Wiseman Michal¹,Mamoor Maha¹,Ehdaie Behfar¹,Laudone Vincent¹,Scardino Peter¹,Eastham James¹,Touijer Karim¹

Affiliation:

1. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York

2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York

3. Institute of Clinical Sciences, Department of Urology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

4. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York

5. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantification of Gleason Pattern 4 Metrics Identifies Pathologic Progression in Patients With Grade Group 2 Prostate Cancer on Active Surveillance;Clinical Genitourinary Cancer;2024-12

2. Japanese clinical practice guidelines for prostate cancer 2023;International Journal of Urology;2024-07-30

3. MRI-guided Focused Ultrasound Focal Therapy for Intermediate-Risk Prostate Cancer: Final Results from a 2-year Phase II Clinical Trial;Radiology;2024-03-01

4. Erratum for: It Is Time to Use Apparent Diffusion Coefficient in Breast MRI Diagnostics;Radiology;2024-03-01

5. Active surveillance should be considered for select men with Grade Group 2 prostate cancer;BMC Urology;2023-09-30